Abstract
This cross-sectional study examines trends in the diagnosis of anogenital warts over the course of 5 years in Connecticut, a state that achieved moderate uptake of human papillomavirus vaccine.
Highlights
Anogenital warts (AGWs) are the earliest clinical manifestation of infection with human papillomavirus (HPV)
The overall proportion of incident AGW diagnoses decreased by 64.5% within the 5-year study period
The rate of incident AGW diagnoses was initially higher in male patients than in female patients (5.8 cases per 1000 visits vs 2.3 cases per 1000 visits; incident rate ratio, 2.53; 95% CI, 1.22 to 5.21; P = .02), this difference largely disappeared by the last year of observation (1.8 cases per 1000 visits vs 0.9 cases per 1000 visits; incident rate ratio, 2.03; 95% CI, 0.65 to 6.42; P = .23)
Summary
Anogenital warts (AGWs) are the earliest clinical manifestation of infection with human papillomavirus (HPV). Two vaccines can prevent most cases of AGW.[1] In 2013, Connecticut reached a significant milestone and became one of the first US states to achieve moderate (>50%) uptake of HPV vaccine in individuals of both sexes.[2] This study aimed to measure trends in the incident diagnoses of AGW over the course of 5 years after the achievement of moderate HPV vaccine uptake. Author affiliations and article information are listed at the end of this article
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
